Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|October 23, 2023
Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant InteractionJeffrey Strik, Loek A W de Jong, Joost Sijm, et al.
Cancer Letters|September 9, 2023
PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancerPeter H J Slootbeek, Joanneke K Overbeek, Marjolijn J L Ligtenberg, et al.
Clinical Pharmacokinetics|July 17, 2023
Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-DarolutamideEva Podgoršek, Niven Mehra, Inge M van Oort, et al.
Cancer Treatment Reviews|October 2, 2022
Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancerKirti K Iyer, Nielka P van Erp, Daniele V F Tauriello, et al.
British Journal of Clinical Pharmacology|February 1, 2018
A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancerGuillemette E Benoist, Maarten J van der Doelen, Rob Ter Heine, et al.
European Journal of Endocrinology|January 12, 2011
Mitotane has a strong and a durable inducing effect on CYP3A4 activityNielka P van Erp, Henk-Jan Guchelaar, Bart A Ploeger, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 10, 2013
A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometryNielka P van Erp, Djoeke de Wit, Henk-Jan Guchelaar, et al.
British Journal of Clinical Pharmacology|November 30, 2019
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized doseKim Westerdijk, Ingrid M E Desar, Neeltje Steeghs, et al.
Biomedical Chromatography : BMC|November 24, 2019
Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MSStefanie D Krens, Eric van der Meulen, Frank G A Jansman, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 21, 2018
Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasmaPauline D J Bollen, Marga J A de Graaff-Teulen, Stein Schalkwijk, et al.
Pageof 11